AstraZeneca Pharma India has partnered with Mankind Pharma to exclusively distribute its anti-asthma drug Symbicort in India. AstraZeneca will retain the intellectual property rights to Symbicort and continue as the marketing authorization holder. Symbicort, a top-selling product globally for AstraZeneca, recorded sales of around $2.4 billion in 2023. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
